Effects of individualized dialysate sodium prescription in hemodialysis – Results from a prospective interventional trial

Radhika Radhakrishnan, Santosh Varughese, Abitha Chandran, Shibu Jacob, Vinoi George David, Suceena Alexander, Anjali Mohapatra, Anna T. Valson, Gopal Basu, Colathur K. Palani,

Indian Journal of Nephrology · 2019 · 21 citations · 11 references

DOIFull text

Open access

Concepts

Abstract

INTRODUCTION: Individualized dialysate sodium prescription does affect weight gain, blood pressure (BP), and intradialytic complications. A prospective interventional trial (Dialysate Individualised Sodium (DISO) trial) was conducted to study this issue in Indian patients. METHODS: Forty patients on thrice-weekly maintenance hemodialysis (HD) for at least 6 weeks were enrolled. The study was performed in two different phases. In the first phase, 12 consecutive HD sessions were done with a standard dialysate sodium concentration of 140 mEq/L. In the second phase, 12 consecutive HD sessions were done with dialysate sodium concentration set to individualized value (mean of pre-HD sodium concentration multiplied by Donnan coefficient of 0.95). Differences in pre- and post-HD sodium, interdialytic weight gain (IDWG), pre- and post-HD BP, thirst scores, and intradialytic adverse events during both phases were assessed. RESULTS: = 0.010). CONCLUSION: The use of individualized dialysate sodium level is safe and results in lower IDWG, pre-HD systolic BP, and intradialytic hypertension in patients on HD.

References

11